We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WTBA:NASDAQWest Bancorporation Analysis

Data as of 2026-05-11 - not real-time

$24.09

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

West Bancorporation posted a solid Q1 2026 earnings beat with net income of $10.6 million and EPS of $0.61, up from $7.4 million and $0.43 in the prior quarter, underscoring a 16.6% revenue growth trajectory. Its dividend yield of 4.15% and a payout ratio under 50% signal a sustainable income stream, while the price‑to‑earnings multiple of 11.6 sits well below the industry average of 16.4, indicating relative cheapness. Technically, the stock trades at $24.09, just above the 20‑day SMA (24.16) and 50‑day SMA (24.02) and comfortably above the 200‑day SMA (22.16), supporting a bullish bias, yet the MACD histogram remains negative and volume is on a downtrend, suggesting short‑term caution. The 30‑day volatility of 28% and a beta near 0.9 reflect heightened price swings typical for regional banks, but the current support at $23.41 and resistance at $25.13 provide a clear trading range. Overall, the combination of earnings momentum, attractive dividend, and valuation discount positions WTBA as a modest upside play pending confirmation of technical strength.
Looking ahead, the DCF‑derived fair value of roughly $53 implies significant long‑term upside, though the modest 6.9% upside/downside metric tempers expectations. The company’s strong cash position ($375 M) relative to debt ($385 M) and a low debt‑to‑equity ratio further mitigate financial risk. Investors should monitor volume trends and MACD signals for entry timing, while the fundamental backdrop remains supportive of a buy‑and‑hold approach.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat and dividend yield
  • Negative MACD histogram and decreasing volume
  • Price near established support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Valuation discount vs industry PE
  • Revenue growth of 16.6% and improving EPS
  • Potential upside toward resistance at $25.13

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value indicating substantial upside
  • Sustainable dividend and strong cash position
  • Undervalued price relative to long‑term fundamentals

Key Metrics & Analysis

Financial Health

Revenue Growth16.60%
Profit Margin35.62%
P/E Ratio11.6
ROE13.88%
ROA0.88%
P/B Ratio1.5
Op. Cash Flow$49.6M
Industry P/E16.4

Technical Analysis

TrendBullish
RSI49.8
Support$23.41
Resistance$25.13
MA 20$24.16
MA 50$24.02
MA 200$22.16
MACDBearish
VolumeDecreasing
Fear & Greed Index90.73

Valuation

Fair Value$53.40
Target Price$25.75
Upside/Downside6.89%
GradeUndervalued
TypeBlend
Dividend Yield4.15%

Risk Assessment

Beta0.92
Volatility28.31%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.